US equities
|
SPCX
$171.09
▲+0.00%
MU
$1,063.96
▲+0.00%
NVDA
$238.90
▲+0.00%
META
$741.90
▲+0.00%
AMZN
$251.40
▲+0.00%
AMD
$631.75
▲+0.00%
STX
$887.09
▲+0.00%
INTC
$116.19
▲+0.00%
SPCX
$171.09
▲+0.00%
MU
$1,063.96
▲+0.00%
NVDA
$238.90
▲+0.00%
META
$741.90
▲+0.00%
AMZN
$251.40
▲+0.00%
AMD
$631.75
▲+0.00%
STX
$887.09
▲+0.00%
INTC
$116.19
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Ambrx, Inc.
Ambrx Raises $78 Million and Completes its ATM Program
March 13, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx to Commence Trading on Nasdaq
March 06, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
March 01, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
February 16, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
February 13, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
February 03, 2023
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
August 29, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
August 16, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
July 05, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
June 28, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
June 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
May 27, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
May 17, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
May 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
April 26, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
April 25, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
April 21, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA
February 15, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee
February 07, 2022
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
November 19, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
November 04, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
November 01, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update
October 28, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO
October 04, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
From
Ambrx, Inc.
Via
Business Wire
Tickers
AMAM
